Safety of advanced therapies in pregnant women with inflammatory bowel disease: a systematic review and Meta-Analysis - PubMed
5 hours ago
- #pregnancy safety
- #inflammatory bowel disease
- #advanced therapies
- Advanced therapies for IBD in pregnant women show an overall favorable safety profile.
- Pooled prevalence rates: 8.2% early pregnancy loss, 8.9% preterm birth, 0.3% stillbirth, 6.6% low birth weight, 2.9% congenital malformations.
- JAK inhibitors and ustekinumab linked to higher early pregnancy loss; vedolizumab associated with higher preterm birth rates.
- Active disease, older maternal age, and longer disease duration are significant predictors of complications.
- Third-trimester exposure associations likely reflect disease severity, not treatment effect, emphasizing the importance of maintaining remission during pregnancy.